We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+4.13%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.68B
AUM Growth
-$63.5M
Cap. Flow
-$190M
Cap. Flow %
-5.16%
Top 10 Hldgs %
14.27%
Holding
1,438
New
94
Increased
433
Reduced
653
Closed
139

Sector Composition

Rank Sector Weight
1 Technology 13.28%
2 Healthcare 12.17%
3 Financials 11.04%
4 Consumer Discretionary 8.91%
5 Industrials 8.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AOD
1226
abrdn Total Dynamic Dividend Fund
AOD
$1.11B
$150K ﹤0.01%
18,000
-89,900
-83% -$743K
QEP
1227
DELISTED
QEP RESOURCES, INC.
QEP
$150K ﹤0.01%
20,800
GME icon
1228
GameStop
GME
$9.76B
$149K ﹤0.01%
+108,800
New +$213K
MDWD icon
1229
MediWound
MDWD
$183M
$148K ﹤0.01%
6,257
+1,571
+34% +$48.5K
JRS icon
1230
Nuveen Real Estate Income Fund
JRS
$250M
$147K ﹤0.01%
14,038
+139
+1% +$1.43K
ANGI icon
1231
Angi Inc
ANGI
$225M
$146K ﹤0.01%
+1,125
New +$173K
DNP icon
1232
DNP Select Income Fund
DNP
$4.07B
$143K ﹤0.01%
12,083
+453
+4% +$5.27K
SHO icon
1233
Sunstone Hotel Investors
SHO
$2.2B
$143K ﹤0.01%
10,404
NTGN
1234
DELISTED
Neon Therapeutics, Inc. Common Stock
NTGN
$143K ﹤0.01%
30,104
+23
+0.1% +$129
JRO
1235
DELISTED
Nuveen Floating Rate Income Opportunty Fund
JRO
$143K ﹤0.01%
14,742
+71
+0.5% +$694
ETW
1236
Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund
ETW
$1.03B
$138K ﹤0.01%
14,143
+40
+0.3% +$391
CSQ icon
1237
Calamos Strategic Total Return Fund
CSQ
$3.23B
$137K ﹤0.01%
10,759
+180
+2% +$2.26K
FTF
1238
Franklin Limited Duration Income Trust
FTF
$232M
$137K ﹤0.01%
14,150
LGF.A
1239
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
$136K ﹤0.01%
11,100
-1,000
-8% -$14.4K
NHS
1240
Neuberger High Yield Strategies Fund Inc
NHS
$251M
$134K ﹤0.01%
11,519
-3,500
-23% -$41K
VOXX
1241
DELISTED
VOXX International Corporation Class A
VOXX
$133K ﹤0.01%
32,000
+5,000
+19% +$20.5K
MAXR
1242
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
$133K ﹤0.01%
17,000
-17,900
-51% -$111K
SBBP
1243
DELISTED
Strongbridge Biopharma plc.
SBBP
$132K ﹤0.01%
42,333
-3,115
-7% -$11.4K
NGVC icon
1244
Vitamin Cottage Natural Grocers
NGVC
$741M
$130K ﹤0.01%
12,971
MEN
1245
DELISTED
Blackrock Muni Enhanced Fund, Inc.
MEN
$130K ﹤0.01%
11,753
-56,484
-83% -$611K
HEXO
1246
DELISTED
HEXO Corp. Common Shares
HEXO
$128K ﹤0.01%
430
+151
+54% +$55.9K
MDR
1247
DELISTED
McDermott International
MDR
$127K ﹤0.01%
13,162
-2,033
-13% -$16.2K
HIE
1248
DELISTED
Miller/Howard High Income Equity Fund
HIE
$125K ﹤0.01%
11,250
UIS icon
1249
Unisys
UIS
$211M
$124K ﹤0.01%
+12,720
New +$131K
VNRX icon
1250
VolitionRx Ltd
VNRX
$9M
$124K ﹤0.01%
1,982
+75
+4% +$4.86K

Similar funds

Oppenheimer & Co's Q2 2019 Portfolio in Review

As of Q2 2019, Oppenheimer & Co held 1,438 positions worth $3.68B, down 1.7% from $3.74B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Oppenheimer & Co withdrew a net $190M in Q2 2019, closing 139 positions and reducing 653 holdings. Its most notable exit was Amber Road Inc, an estimated $2.06M position sold in full.

By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 13% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Oppenheimer & Co opened a new position in Dow Inc worth $8.02M.

  • Oppenheimer & Co's largest Q2 2019 buy was Dow Inc: 162,710 shares worth $8.02M.
  • Oppenheimer & Co added most to Occidental Petroleum in Q2 2019, an estimated $4.3M increase.
  • Oppenheimer & Co's biggest Q2 2019 reduction was Invesco QQQ Trust, cutting an estimated $17.5M.
  • Oppenheimer & Co fully exited Amber Road Inc in Q2 2019, selling an estimated $2.06M.
  • Oppenheimer & Co's ten largest holdings make up 14% of its $3.68B portfolio in Q2 2019.
  • Oppenheimer & Co opened 94 new positions and closed 139 in Q2 2019.
  • Oppenheimer & Co's portfolio value fell 1.7% quarter-over-quarter to $3.68B.

Based on Oppenheimer & Co's 13F filing for Q2 2019, filed 9 Aug 2019.